BioNeutral Group expands testing of sterilants against anthrax

BioNeutral Group, Inc., a Morristown, New Jersey-based specialty life science technology company, announced on Tuesday that it has contracted with Battelle to test its Ygiene sterilant against anthrax spores.

Ygiene is a patent pending antimicrobial that consists of germicidal and sporicidal formulations known as sterilants. The tests are meant to determine the efficacy of Ygiene under conditions that stimulate contaminated environments.

Battelle is one of the largest private and independent research and development organizations in the world.

"We are extremely pleased to have the opportunity to work with a well-known organization like Battelle," Andy Kielbania, a representative of BioNeutral, said. "We believe this non-clinical laboratory testing of our Ygiene sterilants is a critical step in moving our product line into highly specialized applications. The results from this study along with our association with DLA Piper and Senator Daschle will allow us to properly position our products for government applications."

The tests will also determine the applicability of Ygiene for use by homeland security and the military. Testing is expected to begin soon.

BioNeutral Group develops technology platforms to neutralize harmful contaminants of the environment such as toxins, bacteria, viruses, mold, fungi and spores. Its Ygiene brand products have been approved for sale in the United States by the Environmental Protection Agency.